8Li PKT,Leung CB,Chow KM,et al.Hong Kong study using Valsartan in I- gAN(HKVIN)-A double-blind randomized placebo-con-trolled study[J]. Am J Kidney Dis,2006,47(5):751-760.
9Coppo R,Peruzzi L, Amore A,et al.IgACE:a placebo-eontrolled,rand- omized trial of angotensin-converting enzyme inhibitors in childr- en and young people with IgAN and moderate proteinuria[J].J Am Soc Nephrol,2007,18(6): 1880-1888.
10Yamamoto R,Nagasawa Y,Shoji T,et al.Cigarette smoking and prog- ression of IgA nephropathy[J].Am J Kidney Dis,2010,56(2):313-324.
2LI M, FOO JN, WANG JQ, et al. Identification of new suscepti- bility loci for IgA nephropathy in Han Chinese [J]. Nat Com- mun, 2015,6:7270.
3BERTHELOT L, ROBERT T, VUIBLET V, et al. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, au- toantibodies and soluble CD89 complexes [J]. Kidney Int, 2015,88 (4) : 815-822.
4SHEN H, GU W, MAO J, et al. Clinical characteristics of con- comitant nephrotic IgA nephropathy and minimal change disease in children [J ]. Nephron, 2015,130( 1 ) : 21-28.
5COPPO R, DAVIN JC. The difficulty in considering modifiable pathology risk factors in children with IgA nephropathy: cres- cents and timing of renal biopsy [J]. Pediatr Nephrol, 2015,30 (2) : 189-192.
6SUZUKI H, SUZUKI Y, NOVAK J, et al. Development of ani- mal models of human igA nephropathy [J]. Drug Discov Today Dis Models, 2014,11:5-11.
7CHEUNGPASITPORN W, NASR SH, THONGPRAYOON C, et al. Primary IgA nephropathy in elderly patients [J]. Nephrology (Carlton), 2015,20(6) :419-425.
